Form 4: Gilead Sciences CCO Files Future Stock Sale Under 10b5-1 Plan

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, has filed a Form 4 disclosing a planned sale of 3,000 shares of common stock on July 15, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Johanna Mercier, Chief Commercial Officer of Gilead Sciences, Inc. (GILD), reported a planned disposition of 3,000 shares of common stock.
• The transaction is scheduled to occur on July 15, 2025, at a price of $111.03 per share.
• Following this transaction, Ms. Mercier will beneficially own 117,168 shares of Gilead Sciences common stock.
• The sale is being conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on February 20, 2025.

Sentiment

Score: 5

Explanation: A routine insider stock sale executed under a pre-arranged 10b5-1 plan is generally considered neutral, as it is not indicative of new, non-public information.

Positives

• The sale is part of a pre-arranged Rule 10b5-1 trading plan, indicating it is a routine liquidity event and not based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.

Future Outlook

The document indicates a future transaction date of July 15, 2025, for the sale of shares under a pre-existing 10b5-1 plan. No other forward-looking statements or guidance are provided.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitor analysis.

Stakeholder Impact

• The sale of 3,000 shares by a Chief Commercial Officer is a relatively small transaction in the context of a large publicly traded company and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors.

Next Steps

• The planned sale of 3,000 shares of common stock by Johanna Mercier is scheduled for July 15, 2025.

Key Dates

Recommendation

Keywords

Gilead Sciences, GILD, Johanna Mercier, Chief Commercial Officer, Form 4, SEC filing, insider trading, stock sale, 10b5-1 plan, common stock, pharmaceutical, biotechnology